Navigation Links
Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa)
Date:3/7/2008

ed cell aplasia (PRCA) and of severe anemia, with or

without other cytopenias, associated with neutralizing antibodies to

erythropoietin have been reported in patients with chronic renal

failure receiving PROCRIT by subcutaneous administration. If any

patient develops a sudden loss of response to PROCRIT, accompanied by

severe anemia and low reticulocyte count, and anti-erythropoietin

antibody-associated anemia is suspected, withhold PROCRIT and other

erythropoietic proteins. Contact ORTHO BIOTECH (1-888-2ASKOBI or 1-

888-227-5624) to perform assays for binding and neutralizing

antibodies. If erythropoietin antibody-mediated anemia is confirmed,

PROCRIT should be permanently discontinued and patients should not be

switched to other erythropoietic proteins.

-- The safety and efficacy of PROCRIT therapy have not been established in

patients with a known history of a seizure disorder or underlying

hematologic disease (e.g., sickle cell anemia, myelodysplastic

syndromes or hypercoagulable disorders).

-- In some female patients, menses have resumed following PROCRIT therapy;

the possibility of pregnancy should be discussed and the need for

contraception evaluated.

-- Prior to and regularly during PROCRIT therapy monitor iron status;

transferrin saturation should be greater than or equal to 20% and

ferritin should be greater than or equal to 100 ng/mL. During therapy

absolute or functional iron deficiency may develop and all patients

will eventually require supplemental iron to adequately support

erythropoiesis stimulated by PROCRIT.

-- During PROCRIT therapy, blood pressure should be monitored carefully

and aggressively managed, particularly in patients with an underlying

history of hypertension or cardiovascular disease.

-- In studie
'/>"/>

SOURCE Ortho Biotech Products, L.P.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Osteotech to Present at the Canaccord Adams Small-Cap Orthopedics Conference in San Francisco
2. ROBODOC(R) Emerges as a Curexo Technology Company at Upcoming Orthopaedic Surgeons Conference in San Francisco
3. NuVasive to Present at Canaccord Adams Small-Cap Orthopedics Conference
4. SyntheMed to Present at Canaccord Adams Small-Cap Orthopedics Conference
5. Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents
6. Symmetry Medical to Present at Canaccord Adams Small-Cap Orthopedics Conference
7. Kensey Nash to Present at the Canaccord Adams Small-Cap Orthopedics Conference
8. Barr and Ortho Womens Health & Urology in Discussions to Settle ORTHO TRI-CYCLEN(R) LO Patent Litigation
9. Progentix Orthobiology B.V. Closes Series A Financing Round
10. Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) Label Reflects Recommendations from Recent FDA Advisory Committee Meetings
11. Collagen Matrix, Inc. Launches OssiMend(TM) Bone Graft Matrix for Orthopedic and Spine Applications
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 2Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 3Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 4Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 5Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 6Stem cells battle for space 2KV Pharmaceutical Forms Licensing Partnership with Gedeon Richter 49436 1KV Pharmaceutical Forms Licensing Partnership with Gedeon Richter 49436 2KV Pharmaceutical Forms Licensing Partnership with Gedeon Richter 49436 3KV Pharmaceutical Forms Licensing Partnership with Gedeon Richter 49436 4KV Pharmaceutical Forms Licensing Partnership with Gedeon Richter 49436 5Nationwide telemedicine networks are essential for successful health care reform 49432 1Nationwide telemedicine networks are essential for successful health care reform 49432 2Is Your Teenager Using Prescription Drugs Behind Your Back 3F 0ATestCountry Drug Test Panel Numbers Tally with NIDA Fact Sheet Reports on Prescription 49431 1Is Your Teenager Using Prescription Drugs Behind Your Back 3F 0ATestCountry Drug Test Panel Numbers Tally with NIDA Fact Sheet Reports on Prescription 49431 2Is Your Teenager Using Prescription Drugs Behind Your Back 3F 0ATestCountry Drug Test Panel Numbers Tally with NIDA Fact Sheet Reports on Prescription 49431 3